Shares of Global Blood Therapeutics, Inc. (NASDAQ:GBT) have been assigned an average rating of “Buy” from the fifteen ratings firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and twelve have given a buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $57.80.

A number of research analysts have issued reports on the company. SunTrust Banks, Inc. lifted their price objective on Global Blood Therapeutics to $67.00 and gave the company a “buy” rating in a report on Monday, November 6th. BidaskClub raised Global Blood Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, November 1st. Zacks Investment Research cut Global Blood Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, November 7th. Cowen and Company reissued a “buy” rating and set a $83.00 price objective on shares of Global Blood Therapeutics in a report on Thursday, November 9th. Finally, Oppenheimer Holdings, Inc. set a $53.00 price objective on Global Blood Therapeutics and gave the company a “buy” rating in a report on Monday, November 13th.

COPYRIGHT VIOLATION NOTICE: This report was posted by Watch List News and is the property of of Watch List News. If you are reading this report on another publication, it was illegally stolen and republished in violation of US and international trademark & copyright law. The original version of this report can be accessed at https://www.watchlistnews.com/global-blood-therapeutics-inc-gbt-given-consensus-rating-of-buy-by-brokerages/1722584.html.

Global Blood Therapeutics (NASDAQ GBT) traded up $0.05 on Thursday, reaching $38.35. 693,800 shares of the company’s stock were exchanged, compared to its average volume of 999,501. Global Blood Therapeutics has a 1 year low of $13.35 and a 1 year high of $43.95.

Global Blood Therapeutics (NASDAQ:GBT) last posted its quarterly earnings results on Thursday, November 2nd. The company reported ($0.66) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.62) by ($0.04). During the same period in the previous year, the business posted ($0.58) EPS. equities analysts forecast that Global Blood Therapeutics will post -2.53 EPS for the current fiscal year.

In related news, insider Jung Choi sold 3,000 shares of Global Blood Therapeutics stock in a transaction dated Friday, September 29th. The stock was sold at an average price of $30.00, for a total value of $90,000.00. Following the completion of the transaction, the insider now directly owns 140,055 shares of the company’s stock, valued at $4,201,650. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Peter Radovich sold 12,500 shares of Global Blood Therapeutics stock in a transaction dated Monday, October 30th. The shares were sold at an average price of $35.00, for a total value of $437,500.00. Following the completion of the transaction, the vice president now directly owns 2,684 shares of the company’s stock, valued at $93,940. The disclosure for this sale can be found here. Insiders sold 91,500 shares of company stock valued at $3,093,350 over the last ninety days. 5.30% of the stock is currently owned by company insiders.

Several institutional investors have recently added to or reduced their stakes in GBT. Teachers Advisors LLC raised its holdings in shares of Global Blood Therapeutics by 426.2% in the first quarter. Teachers Advisors LLC now owns 156,195 shares of the company’s stock valued at $5,756,000 after buying an additional 126,513 shares during the last quarter. Legal & General Group Plc raised its holdings in Global Blood Therapeutics by 10.1% during the 1st quarter. Legal & General Group Plc now owns 4,816 shares of the company’s stock worth $178,000 after purchasing an additional 440 shares during the last quarter. Vanguard Group Inc. raised its holdings in Global Blood Therapeutics by 40.1% during the 1st quarter. Vanguard Group Inc. now owns 2,535,980 shares of the company’s stock worth $93,451,000 after purchasing an additional 726,366 shares during the last quarter. Geode Capital Management LLC raised its holdings in Global Blood Therapeutics by 59.7% during the 1st quarter. Geode Capital Management LLC now owns 244,667 shares of the company’s stock worth $9,015,000 after purchasing an additional 91,498 shares during the last quarter. Finally, BlackRock Inc. raised its holdings in Global Blood Therapeutics by 4,675.5% during the 1st quarter. BlackRock Inc. now owns 2,618,847 shares of the company’s stock worth $96,503,000 after purchasing an additional 2,564,008 shares during the last quarter. 85.03% of the stock is owned by institutional investors and hedge funds.

Global Blood Therapeutics Company Profile

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Analyst Recommendations for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.